Time filter

Source Type

Lin J.,Southern Medical University | Zhang X.-M.,Southern Medical University | Yang J.-C.,Guangzhou Liu Hua Qiao Hospital | Ye Y.-B.,Southern Medical University | Luo S.-Q.,Southern Medical University
Archives of Medical Research | Year: 2010

Background and Aims: Glioblastoma is a deadly primary brain tumor with great resistance to radiotherapy. To reverse its radioresistance is important for improving prognosis. Gamma-secretase inhibitors (GSI) have been proven to have anti-tumor effects, yet the knowledge of their influences on glioblastomas is still limited. Methods: The cytotoxic effects of GSI-I (a tripeptide GSI) on glioblastoma cell lines U87 and U251 were assessed by MTT assay, and the low concentration that did not induce significant cell death was determined. The in vitro radiosensitization effects of this low concentration of GSI-I were evaluated by cell colony forming assays. The CD133+ cell fractions before and after radiation with or without treatment of GSI-I were analyzed by flow cytometry. Then CD133+ and CD133- glioblastoma cells were sorted by magnetic activated cell sorting (MACS), and the radiosensitization effects of GSI-I on the two cell subtypes were investigated separately. Finally, the cytotoxic effects of GSI-I on CD133+ and CD133- glioblastoma cells were examined, respectively, and the expression of the Notch pathway components between the two cell subtypes were compared. In addition, the anti-tumor effects of GSI-I were confirmed by in vivo experiments. Results: GSI-I at a low concentration sensitized U87 and U251 cells to radiation by depletion of radioresistant CD133+ cells. CD133+ U87/U251 cells displayed preferential sensitivty to low concentrations of GSI-I, which may be related to the higher expression of the Notch signaling pathway in these cells. Conclusions: Combining GSI-I with radiotherapy may represent a promising strategy for treating radioresistant gliomas. © 2010 IMSS. Source

Yang T.,Guangzhou Liu Hua Qiao Hospital | Zheng X.-F.,Guangzhou Liu Hua Qiao Hospital | Li M.,Guangzhou Liu Hua Qiao Hospital | Lin X.,Southern Medical University | Yin Q.-S.,Guangzhou Liu Hua Qiao Hospital
Asian Pacific Journal of Cancer Prevention | Year: 2013

Therapeutic effects of zoledronic acid (ZOL) on giant cell tumour of bone (GCT) have been proven. Apoptosis induction was considered to be one of the mechanisms of ZOL tumour inhibition. In this study, we presented the possibility of an osteogenic differentiation stimulation mechanism of ZOL and further investigated dosage and time effects. We treated stromal cells of GCT (GCTSC) with ZOL for 48 hours at different concentrations (0 μM, 0.01 μM, 0.1 μM, 1 μM, 5 μM, 30 μM) and assessed apoptotic and osteogenic differentiation markers with immunohistochemical techniques and real-time quantitative RT-PCR. Our results suggested that ZOL enhanced mRNA expression of Cbfa-1, osterix and osteocalcin genes with a maximum effect at 1μM in GCTSC. Time course experiments indicated a time dependent osteogenic differentiation effect. In conclusion, ZOL may be considered as an adjuvant in the treatment of GCT not only by inducing apoptosis but also by stimulating osteogenic differentiation of remaining tumor stromal cells after surgery. Source

He B.,China Meitan General Hospital | He B.,Southern Medical University | He G.,Southern Medical University | Zheng X.,Guangzhou Liu Hua Qiao Hospital | And 3 more authors.
Experimental and Therapeutic Medicine | Year: 2016

The inhibitory effect of bone morphogenetic protein-2 (BMP-2) on the proliferation of giant cell tumor of bone stromal cells (GCTSCs) has not been fully elucidated. Therefore, the aim of this study was to evaluate the role of recombinant human BMP‑2 (rhBMP‑2) in the growth of GCTSCs. The effects of exposure to different concentrations of rhBMP‑2 (0, 10, 100 and 300 ng/ml) for 1, 3, 5 and 7 days on GCTSC proliferation were examined by 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assay. In addition, the effect of treatment with rhBMP‑2 (0 or 10 ng/ml) for 48 h on the cell cycle pattern of GCTSCs was examined by flow cytometry. The apoptosis‑inducing effect of rhBMP‑2 (0 or 10 ng/ml) in GCTSCs was also determined by flow cytometry after 48 and 72 h. In addition, western blot assays were conducted to determine whether rhBMP‑2 acts on non‑Smad mitogen‑activated protein kinase (MAPK) signaling pathways, namely extracellular signal‑regulated kinase (ERK1/2), p38 and c‑jun‑N‑terminal kinase (JNK) pathways. The proliferation of GCTSCs treated with rhBMP‑2 (10, 100 or 300 ng/ml) for 5 or 7 days was significantly inhibited in a non dose‑dependent and non‑time‑dependent manner (P<0.05). The treatment of GCTSCs with rhBMP‑2 (10 ng/ml) for 48 h had no effect on cell cycle distribution. The apoptosis of GCTSCs induced by exposure to rhBMP‑2 (10 ng/ml) for 48 or 72 h was significant (P<0.05). Expression levels of phospho‑ERK1/2, phospho‑p38 and phospho‑JNK increased significantly when GCTSCs were treated with rhBMP‑2 (10 ng/ml) for 72 h (P<0.05). The results indicate that rhBMP‑2 has no stimulatory effect on GCTSC growth. However, it may lead to the apoptosis of GCTSCs by non‑Smad MAPK signaling pathways. © 2016, Spandidos Publications. All rights reserved. Source

Huang H.,Guangzhou Liu Hua Qiao Hospital | Zheng X.,Guangzhou Liu Hua Qiao Hospital | Li P.,Guangzhou Liu Hua Qiao Hospital | Shen H.,Guangzhou Liu Hua Qiao Hospital
International Journal of Surgery | Year: 2013

Background: With the continuous development of arthroscopic techniques, the majority of superior labrum anterior-posterior (SLAP) lesions can be treated with minimally invasive endoscopic repair. The aim of this study was to determine the efficacy of arthroscopic capsulolabral reconstruction of SLAP lesions with extensive tears. Methods: Eighteen patients with SLAP lesions with extensive tears (median age, 27.50 years) were included in this study. Twelve patients had type-V SLAP lesions, 4 patients had type-VIII SLAP lesions, and 2 patients had deeply located SLAP lesions. The average duration of follow-up was 15.83 months (range, 11-22 months). Outcome measures included shoulder range of motion (ROM), American Shoulder and Elbow Surgeons (ASES) and Constant-Murley scores, and visual analogue scale (VAS) pain score. Results: After arthroscopic surgery, shoulder forward flexion, shoulder external rotation, and external rotation in 90° of abduction were significantly greater than before surgery (169.5° vs. 165.5°, P=0.001), (90° vs. 63.5°, P<0.001), and (90° vs. 81.5°, P=0.004), respectively. Median ASES and Constant-Murley scores after surgery were both 94 as compared to 77.0 and 77.5, respectively, before surgery (both, P<0.001). The median VAS score decreased to 1.5 after surgery as compared to 6 before surgery (P<0.001). Conclusions: Arthroscopic repair of SLAP lesions with extensive tears can achieve good outcomes. © 2013 Surgical Associates Ltd. Source

Ma X.-Y.,Guangzhou Liu Hua Qiao Hospital | Yin Q.-S.,Guangzhou Liu Hua Qiao Hospital | Wu Z.-H.,Guangzhou Liu Hua Qiao Hospital | Xia H.,Guangzhou Liu Hua Qiao Hospital | And 2 more authors.
Spine | Year: 2010

Study Design. A cadaveric specimen study. Objectives. To determine the applicability of a modified C2 translaminar screw placement in the general adult population and to provide pertinent clinical data for screw insertion. Summary of Background Data. C2 intralaminar screw fixation has recently been popularized, but this technique carries a potential drawback that the screw may breakout ventrally into the spinal canal. For this reason, a modified C2 translaminar screw fixation technique was developed to intraoperatively verify screw position and thereby decrease the risk or canal compromise. To our knowledge, there has been not an anatomic study evaluating this modification of the translaminar screw technique. Methods. The tips of the modified screws were aimed such that they exited the dorsal cortex of the center of the contralateral lateral mass, achieving bicortical fixation. A total of 120 adult C2 vertebrae were evaluated bilaterally for the following: thickness of the cranial, midportion, and caudal edge of C2 lamina; the heights of the spinous process, lamina, and lateral mass; inclination angle of the laminae, screw projection length, and trajectory angle of cranial and caudal C2 translaminar screw. Results. A total of 83.3% specimens had bilateral laminar thicknesses ≥4.0 mm and a spinous process height ≥9.0 mm; 5% had a laminar thickness less than 4.0-mm bilaterally; 9.2% had a laminar thickness less than 4.0 mm on one side; 2.5% had a spinous process height lower than 9.0 mm. Conclusion. A large percentages of C2 laminae are of sufficient size to safely accommodate a bicortical 3.5-mm diameter screw. The thickness of the lamina and the height of the spinous process are the 2 limiting factors for safe translaminar screws placement. Using a bicortical technique confirms the position of the screw and thereby helps to decrease the risk of neurologic injury from screw penetration of the inner cortex of the lamina. © 2010, Lippincott Williams & Wilkins. Source

Discover hidden collaborations